Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Vistagen Therapeutics Inc (NQ: VTGN )

3.870 -0.330 (-7.86%)
Streaming Delayed Price Updated: 3:59 PM EDT, Oct 3, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vistagen Therapeutics Inc

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
FDA Provides Positive Feedback to Vistagen Regarding Use of the Liebowitz Social Anxiety Scale (LSAS) as an Endpoint in Phase 3 Development of Fasedienol (PH94B) for Treatment of Social Anxiety Disorder
From Vistagen
Via Business Wire
Why VistaGen Therapeutics Shares Are Trading Higher Today
VistaGen Therapeutics (NASDAQ: VTGN) shares are trading higher on Wednesday after the company announced data from its Phase 3 open-label study evaluating safety and tolerability of fasedienol.  
Via Benzinga
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Positive Results from PH94B Phase 3 Study
Via Investor Brand Network
VistaGen Therapeutics's Return On Capital Employed Insights
Via Benzinga
VistaGen Shares Plunge Amid Uncertainty Around Its Anxiety Trial
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Vistagen Announces Positive Data in Fasedienol (PH94B) Phase 3 Open-Label Study in Adults with Social Anxiety Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Provides Update on Phase 1 Clinical Trial of Proprietary PH10
Via Investor Brand Network
Preview: VistaGen Therapeutics's Earnings
Via Benzinga
Vistagen Announces Completion of Last Patient, Last Visit in Phase 1 Clinical Trial of Itruvone (PH10), an Investigational Pherine Nasal Spray for Major Depressive Disorder
From Vistagen
Via Business Wire
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Participate at Upcoming Health Care Conference
Via Investor Brand Network
Vistagen to Present at Cowen 43rd Annual Health Care Conference
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Secures US Patent for PH80 Nasal Spray for Treatment of Migraine
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Announces Issuance of U.S. Patent for PH80 Nasal Spray for Treatment of Migraine
From Vistagen
Via Business Wire
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
It's time to start another day of trading with a breakdown of the biggest pre-market stock movers investors need to watch for Tuesday! 
Via InvestorPlace
Why Frequency Therapeutics Are Trading Lower By 82%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Gainers Vallon Pharmaceuticals, Inc. (NASDAQ: VLON) shares jumped 120.5% to $1.02 after jumping over 72% on Friday. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Why Alteryx Shares Are Trading Higher By Over 10%; Here Are 20 Stocks Moving Premarket
Gainers 
Via Benzinga
Why Hempacco Are Trading Lower By 58%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Gainers SeqLL Inc. (NASDAQ: SQL) shares jumped 120% to $1.85 after dropping around 39% on Thursday. SeqLL recently announced the establishment of a two-year Cooperative Research and Development... 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Wednesday's Intraday Session
Via Benzinga
InvestorNewsBreaks — VistaGen Therapeutics Inc. (NASDAQ: VTGN) Releases Q3 2023 Financial Results, Corporate Update
Via Investor Brand Network
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Via Benzinga
Why Sintx Technologies Shares Are Trading Lower By 38%; Here Are 20 Stocks Moving Premarket
Gainers PainReform Ltd. (NASDAQ: PRFX) shares rose 89.5% to $0.9475 in pre-market trading. PainReform reported receipt of extension to Aug. 7, 2023 to meet the Nasdaq's minimum bid price requirement. 
Via Benzinga
Vistagen Provides Corporate Update and Reports Fiscal 2023 Third Quarter Financial Results
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) to Host Q3 Fiscal 2023 Results Call and Webcast
Via Investor Brand Network
Vistagen to Report Fiscal Year 2023 Third Quarter Financial Results on February 7, 2023
From Vistagen
Via Business Wire
InvestorNewsBreaks – VistaGen Therapeutics Inc. (NASDAQ: VTGN) Announces Closing of Strategic Acquisition
Via Investor Brand Network
Topics Intellectual Property
Exposures Intellectual Property
Vistagen Announces Closing of Pherin Pharmaceuticals Acquisition
From Vistagen
Via Business Wire
Why AppTech Payments Are Trading Lower By Over 25%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Gainers 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.